AG vs AXTA

The company exhibits weak financial health with a Piotroski F-Score of 4/9, indicating marginal stability, and lacks an Altman Z-Score, raising concerns about financial distress risk. Despite strong recent price performance and robust revenue growth (95.10% YoY), the stock appears significantly overvalued with a P/E of 169.60 versus sector average of 26.34 and a Graham Number of just $4.23, far below the current price of $25.44. Earnings quality is poor, with a track record of missing estimates in 3 of the last 4 quarters and an average surprise of -24.17%. While balance sheet metrics like low debt/equity (0.08) and strong liquidity (current ratio 3.38) are positives, weak ROE (4.21%) and inconsistent profitability undermine long-term value creation.

AXTA's deterministic scorecard shows a Piotroski F-Score of 4/9, indicating stable but not strong financial health, and the absence of an Altman Z-Score prevents a full distress risk assessment. The stock trades below the growth-based intrinsic value of $48.10 but above the conservative Graham Number of $22.25, suggesting mixed valuation signals. Despite solid profitability metrics like a 21.33% ROE and consistent earnings beats, revenue is contracting YoY by 2.40%, and insider activity is bearish with recent selling. Analysts recommend a 'buy' with a $36.71 target, implying moderate upside from current levels around $33.62.